Plus: hormone infusion for weight loss; metformin & reduced COVID-19 mortality; more
Can't see the images? View as webpage.
Facebook
Twitter
LinkedIn
To ensure that you never miss an issue, please whitelist us.

Saturday, Sept. 19, 2020 : Issue #1064

TOP STORIES - Diabetes News & Research

Simple Strategies to Prevent Cardiovascular Complications in T2D

Heart Rate Variability as a Predictor for the Development of Diabetes

An Alternative Option for Weight and Glycemia Reduction
Letter from the Editor

Imagine if you had a dollar for every time a patient came to your office with the holy grail to cure their diabetes. While you could probably retire off of all those dollars, you probably noticed that every time they show you the cure, it will start working "soon," and when they come back nothing has changed.

This week our intern Nour Salhab, Pharm.D. Candidate, USF College of Pharmacy, has found scientific evidence that a holy grail does exist and it works both for diabetes and obesity.

Click here to find out why Nour was excited when she found this article.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief
Advertisement

TOP STORIES - Diabetes News and Research

Simple Strategies to Prevent Cardiovascular Complications in T2D
Explore three methods to prevent future acute myocardial infarction with diabetes as an underlying agent.
READ MORE
Heart Rate Variability as a Predictor for the Development of Diabetes
Decreased vagal tone and changes in sympathetic activity may precede the development of cardiometabolic disease or diabetes.
READ MORE
An Alternative Option for Weight and Glycemia Reduction
Infusion of certain hormones could help in reducing patient weight and glucose levels.
READ MORE

Did You Know? Metformin Is Associated with a 70% Reduced Mortality in Those with Diabetes and Covid-19


Accumulating observational data suggest that metformin use in patients with type 2 diabetes might reduce the risk of death from COVID-19.

The latest results were published online  on July 31. The researchers found that among more than 600 patients with diabetes and COVID-19, the use of metformin was associated with a nearly 70% reduction in mortality after adjustment for multiple confounders—data from four previous studies that also show a decrease in mortality among metformin users compared to nonusers. Taken together, the four observational studies showed that metformin had a positive effect, with an overall 25% reduction in death (P < .00001), albeit with relatively high heterogeneity. The largest of these, from the United States, included 6,256 patients hospitalized with COVID-19 and involved propensity matching. A significant reduction in mortality with metformin use was seen in women but not men (odds ratio, 0.759).

Because metformin exerts various effects beyond its glucose-lowering action, among which are anti-inflammatory effects, it may be speculated that this biguanide might positively influence the prognosis of patients with type 2 diabetes hospitalized for COVID-19. Given the potential confounders inherently found in observational studies, caution is required before drawing any firm conclusions in the absence of randomized controlled trials.

The increasing observational data suggest that metformin use in patients with type 2 diabetes might reduce the risk of death from COVID-19. Still, the randomized trials needed to prove this are unlikely to be carried out, according to experts.

medRxiv. Published online July 31, 2020. Full text; Diabetes Metab. Published online, August 1, 2020. Full text
“Does Metformin Reduce Risk for Death in COVID-19?” Medscape-Aug. 14, 2020

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Brianna Belton, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences

Stephen Rubano, PharmD. Candidate, USF Taneja College of Pharmacy 

Nour Salhab, Pharm.D. Candidate, USF College of Pharmacy

Peter Jay Won, Pharm.D. Candidate, University of South Florida, Taneja College of Pharmacy

Sandra Zaki, PharmD Candidate, Florida A&M University

 About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com
Facebook
Twitter
LinkedIn
©2020 HIPER, LLC. All rights reserved.

This email was sent by eHealthcare Solutions on behalf of:
Diabetes In Control
810 Bear Tavern Rd, Suite 102
Ewing, NJ, 08628, United States


DiabetesInControl.com | Contact Us
Subscription Center | Update Profile
Unsubscribe